SELL and neoplasm: Metelitsa et al. showed that CD62L+ NKT cells outperform CD62L− NKT cells in terms of proliferation and survival after repeated antigen stimulation, and that CD62L+ NKT cells have better persistence and anti-tumor activity in mouse tumor models [409].